544172 Stock Overview

Operates as a life sciences commercialization company in India, the United States, Europe, and internationally. More details

544172 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	4/6
Financial Health	5/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (39.2x) is below the Life Sciences industry average (46.6x)

Earnings are forecast to grow 18.04% per year

Earnings have grown 24.3% per year over the past 5 years

Risk Analysis

No risks detected for 544172 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Indegene Limited Competitors

Sai Life Sciences

NSEI:SAILIFE

₹156.1b

Syngene International

NSEI:SYNGENE

₹298.9b

Akums Drugs and Pharmaceuticals

NSEI:AKUMS

₹88.3b

Innova Captab

NSEI:INNOVACAP

₹52.9b

Price History & Performance

Summary of share price highs, lows and changes for Indegene
Historical stock prices
Current Share Price	₹629.20
52 Week High	₹736.60
52 Week Low	₹468.90
Beta	0
1 Month Change	-0.24%
3 Month Change	-8.65%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	10.26%

Recent updates

Shareholder Returns

	544172	IN Life Sciences	IN Market
7D	4.7%	4.8%	1.6%
1Y	n/a	49.5%	5.5%

Return vs Industry: Insufficient data to determine how 544172 performed against the Indian Life Sciences industry.

Return vs Market: Insufficient data to determine how 544172 performed against the Indian Market.

Price Volatility

Is 544172's price volatile compared to industry and market?
544172 volatility
544172 Average Weekly Movement	5.2%
Life Sciences Industry Average Movement	6.7%
Market Average Movement	6.3%
10% most volatile stocks in IN Market	9.1%
10% least volatile stocks in IN Market	4.3%

Stable Share Price: 544172 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 544172's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1998	4,367	Manish Gupta	www.indegene.com

Indegene Limited operates as a life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies.

Indegene Limited Fundamentals Summary

How do Indegene's earnings and revenue compare to its market cap?
544172 fundamental statistics
Market cap	₹149.29b
Earnings (TTM)	₹3.84b
Revenue (TTM)	₹27.57b

39.2x

P/E Ratio

5.5x

P/S Ratio

Is 544172 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
544172 income statement (TTM)
Revenue	₹27.57b
Cost of Revenue	₹588.00m
Gross Profit	₹26.98b
Other Expenses	₹23.14b
Earnings	₹3.84b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	16.04
Gross Margin	97.87%
Net Profit Margin	13.93%
Debt/Equity Ratio	3.7%

How did 544172 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/07 15:17
End of Day Share Price	2025/02/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Indegene Limited is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Rajiv Berlia	Citigroup Inc
Rishi Jhunjhunwala	IIFL Research
Ankur Rudra	J.P. Morgan